A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo

You likely can't join if

• • Unable to consent (adults lacking capacity); • Partecipants that have diagnosis of other type of vitiligo including segmental and mixed vitiligo; • Has ≥50% leukotrichia on face or body; • Unable to return for follow-up visits; • Pregnant women and/or breastfeeding, or those who have recently delivered a baby within the past 6 months; • Has any other dermatological diseases that would interfere with vitiligo assessments; • History of type I or II diabetes • Has a transplanted organ, which requires continued immunosuppression; • Systemic immunosuppressive medication (oral corticosteroids) within prior 4 weeks; • Currently undergoing UVB light therapy or history of light therapy within the past 8 weeks; • Has a history of any malignancy, except for localized in situ skin carcinoma; • Has had major surgery within 3 months prior to Screening OR has a major surgery planned during the study; • Prior/Concurrent investigational clinical study experience; • Enrolled in a clinical study of any other investigational drug or device; • Diabetes, liver disease, or kidney disease; • Hypoglycemia as defined by fasting blood glucose <70 mg/dL assessed at a fasting study visit; • ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: • Absolute neutrophil count of <2.5 x 109/L (<2500/mm3); • Hemoglobin <10.0 g/dL or hematocrit <30%; • Platelet count below the lower limit of normal (LLN) at Screening; • Absolute lymphocyte count of <0.8 x 109 /L (<800/mm3); • Serum creatinine > upper limit of normal (ULN) or eGFR <60 ml/min/1.73m2 based on the age appropriate calculation. • Enzymes aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >2 times the ULN; • Total bilirubin 1.5 times the ULN; subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ULN; • Creatine kinase (CK) >3 times the ULN and positive urine myoglobin; • In the opinion of the investigator, have any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject’s participation in the study. • In the investigator's judgment, any concomitant diseases or therapies that might interfere with the reliability of the study analyses.